Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Phase IIb Trial of Bevacizumab Added to Temozolomide ± Irinotecan for Children With Refractory/Relapsed Neuroblastoma - BEACON-Neuroblastoma Trial

NCT02308527 is registered in ClinicalTrials.gov with University of Birmingham as lead sponsor.

NCT NCT02308527
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02308527 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Phase IIb Trial of Bevacizumab Added to Temozolomide ± Irinotecan for Children With Refractory/Relapsed Neuroblastoma - BEACON-Neuroblastoma Trial
Lead sponsor
University of Birmingham
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2013
Completion date
February 18, 2026
Enrollment
225 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma